Another breakthrough in the research and development of Dongfang Baitai antibody!
- Categories:Company News
- Author:
- Origin:Dongfang Baitai
- Time of issue:2022-05-23
- Views:764
(Summary description)At present, bispecific antibodies are rare in China. There is no corresponding product on the market. With the maturity of bispecific antibody technology and increasing investment, bispecific antibody has gradually become a new upstart in antibody industry.
Another breakthrough in the research and development of Dongfang Baitai antibody!
(Summary description)At present, bispecific antibodies are rare in China. There is no corresponding product on the market. With the maturity of bispecific antibody technology and increasing investment, bispecific antibody has gradually become a new upstart in antibody industry.
- Categories:Company News
- Author:
- Origin:Dongfang Baitai
- Time of issue:2022-05-23
- Views:764
At present, bispecific antibodies are rare in China. There is no corresponding product on the market. With the maturity of bispecific antibody technology and increasing investment, bispecific antibody has gradually become a new upstart in antibody industry.
What is a bispecific antibody?
Bispecific antibody is a product of genetic engineering. It has two specific antigen binding sites, which can interact with target cells and functional cells at the same time, thereby enhancing the killing effect on target cells. Compared with ordinary antibodies, bispecific antibodies have significant advantages such as stronger specificity, guiding T cells to kill tumors, and reducing off target toxicity.
Bispecific antibody is one of the main directions of biological medicine in the future. Although the concept of double specificity has appeared for more than 30 years. It has been considered as a potential cancer treatment drug. However, many technical challenges have only been resolved in recent years.
In December 2014, FDA approved the world's first bispecific antibody blinatumomab (Blincyto) for the treatment of acute lymphoid leukemia (ALL). Since then, more than 120 kinds of bispecific antibody molecules have entered the clinical pipeline.
As one of the branches of antibody drugs, the bispecific antibody drug market is gradually heating up in China under the upsurge of large investment by global biotechnology companies and the growing maturity of technology in this field, which has become a new upstart in the antibody industry.
In this context, bispecific antibodies are still rare in China. There are huge opportunities: fewer participating enterprises, large market and wide future space. Most of the domestic bispecific antibody projects are still in the germination stage, and the products are in the pre clinical state. With the arrival of the golden age, comprehensive antibody drug enterprises with mature R&D capabilities and product lines in the field and enterprises with first mover advantages in the industry will be in the forefront.
Dongfang Baitai's antibody upstart
Dongfang Baitai focuses on the research of antibody drugs mainly for the treatment of major diseases and new products of preventive biological medicine. The company started the construction of dual specific platform in 2015. At present, several bispecific antibody projects are in progress. We have made bold innovation and made many major breakthroughs in the frontier field of biomedicine. At the same time, great attention is paid to intellectual property protection. We also explored the transformation and application of some scientific research achievements, making contributions to the promotion of the whole monoclonal antibody industry.
Recently, the JY016 project of Dongfang Baitai for EGFR/CD3 bispecific antibody drugs for lung cancer and colorectal cancer has solved the key core technology of bispecific antibody research and development. It has obtained the invention patent certificate granted by the China Intellectual Property Office, and has applied for international patents.
JY016 is a bispecific antibody drug targeting EGFR/CD3. There is no variety on the market internationally, and no one in China has applied for clinical treatment. It has the opportunity to become a drug of First in class.
EGFR is a good and classic anti-tumor target. The EGFR antibody drugs that have been marketed now include cetuximab, paniximab, nituzumab, etc. The existing monoclonal antibody drugs have significant efficacy and good market sales. JY016, a "two pronged approach", found in the in vivo and in vitro pharmacodynamics study that the efficacy of the bispecific antibody was superior to the currently marketed monoclonal antibody drugs. And there is no significant side effect. There is a great possibility of the final drug.
The JY016 project has independently innovated and established a bispecific antibody engineering construction platform. If successfully developed, it will ease the serious shortage of the declaration of bispecific antibodies in China. It can meet the major needs of cancer patients in China for anticancer drugs. It has good economic and social benefits. At the same time, it plays a positive role in the development of China's bio pharmaceutical industry.
Dongfang Baitai has initiated the research and development of biological antibody drugs for many years. At present, it has formed a certain scale. The company's R&D pipeline is very rich, including monoclonal antibody, ADC drug, bispecific antibody, vaccine, etc. We have made full use of our own advantages, combined innovation and imitation, and successively set up more than 20 projects to research and develop biotechnology drugs. It covers many disease fields such as tumor, diabetes, autoimmune and ophthalmic diseases. At present, it has 5 clinical approvals issued by the State Food and Drug Administration. It is estimated that two new varieties of monoclonal antibodies will be applied for clinical use in 2018.
Scan the QR code to read on your phone
推荐新闻
Follow us

Follow the official WeChat official account
Or search "Oriental Baitai"
More exciting waiting for you!
Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com
Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd SEO 京ICP备********号